Impaired glucose tolerance (IGT) and Type II (noninsulin-dependent) diabetes mellitus result from different contributions of deficient insulin secretion and impaired insulin sensitivity [1±8]. Routine quantification of these abnormalities is rarely done as simple, user friendly methods have not been validated or received general approval [9, 10] . The choice of therapy might depend on the causative pathophysiology in a patient and, with the prospect of insulin-sensitising drugs as well as life-style changes to improve insulin sensitivity, routine assessment of insulin sensitivity might become more appropriate than at present [11, Diabetologia (1999) 
12]. We have investigated different methods for measuring insulin sensitivity, to determine which is most informative across a range of glucose tolerance.
Insulin sensitivity is usually measured by assessing the relation between plasma insulin and an insulindependent metabolic variable such as plasma glucose [13±15] . The euglycaemic hyperinsulinaemic clamp is the ªgold standardº for measuring insulin sensitivity [13, 16] , but repeat plasma glucose sampling makes it both labour-intensive and costly. The widely used Minimal Model (MinMod) approach estimates insulin sensitivity by analysing glucose/insulin relations during a frequently sampled intravenous glucose tolerance test (FSIVGTT), modified with tolbutamide or exogenous insulin to obtain sufficiently high insulin concentrations to assess the glycaemic response to insulin [13±19] . Although easier to do than a clamp, it still requires approximately 30 timed-samples over a 2 1/2-h period, and iterative determination of model variables can fail in subjects with IGT or Type II diabetes, unless insulin or tolbutamide are added [20, 21] . Doubts on its interpretation have also been raised from labelled studies [22] , so that alternative approaches for routine measurement of insulin sensitivity are required.
The homeostasis model assessment (HOMA) and continuous infusion of glucose with model assessment (CIGMA) models and the short insulin tolerance tests (ITT) provide insulin sensitivity estimates that are easier to carry out [23±28] . The HOMA-CIGMA is a structural model of glucose/insulin interaction, with mathematical equations describing the functioning of the major effector organs. Assessment of the glucose and insulin concentrations in each person allows evaluation of the combination of deficient beta-cell function and impaired insulin sensitivity that are present. The simplest application is assessing the basal homeostasis by measuring fasting glucose and insulin concentrations with HOMA [24, 27] . Since the basal concentrations of glucose and insulin are low and require precise and sensitive assays, the alternative method evaluates the near-steady state glucose/insulin concentrations after 2 h of a low dose, constant glucose infusion that induces plasma glucose and insulin concentrations similar to postprandial concentrations (modelled with CIGMA) [23, 25±27] . Homeostasis model assessment and CIG-MA have been validated against independent measures of insulin sensitivity and beta-cell function, including clamp-derived measures [23, 24] and are more practical, cheaper and less invasive than FSIVGTT. The short ITT is a simple direct estimate of in vivo insulin action, validated against the euglycaemic clamp, that measures the decrease in plasma glucose following an insulin bolus in the fasting state [23] . It does not estimate beta-cell function whereas the FSIVGTT, HOMA and CIGMA assess both insulin sensitivity and beta-cell function.
Methods that assess performance and agreement between tests do not provide information on their discriminatory value in clinical practice [29±33]. Validation of insulin sensitivity tests has usually consisted of correlation analysis with a reference method (usually the euglycaemic clamp), reproducibility measures and estimation of intra-subject or between-subject variation. These estimates are not combined to allow assessment of the ability of tests to discriminate in practice between subjects and to rank them for their insulin sensitivity. Assessment of the relative performance of tests requires assessment of both the reproducibility and the degree to which they are sensitive to differences within a population.
Recently a practical means of comparing imprecise tests that takes into account imprecision of tests and the degree to which they can assess differences between subjects has been developed [34] . In this study, we have assessed different insulin sensitivity tests by: firstly, measuring their ability to distinguish the insulin sensitivity of different subjects by means of their discriminant ratio; secondly, determining the degree to which different tests measure the same physiological function, using Pearson correlation coefficients adjusted for attenuation due to test imprecision and thirdly, defining unbiased lines of equivalence relating one test to another and taking into account imprecision of both tests.
Various in vivo tests of insulin sensitivity (FSIVGTT, HOMA, CIGMA, and ITT) were compared using this methodology to determine which was most efficient. This analysis was carried out over a range of subjects selected to span glucose tolerance from NGT to IGT and Type II diabetes. We also compared the respective performance of immunoreactive and specific insulin as input to estimate insulin sensitivity using HOMA and CIGMA.
Subjects and methods
Subjects. White Caucasians subjects (n = 24) participated in the study, which was approved by the Central Oxford Research and Ethics Committee. Glucose tolerance ranged from normoglycaemia to World Health Organisation (WHO)-defined diabetes mellitus [35] . From the subjects seven were non-diabetic with no first degree relatives with diabetes (NGT group). A further eight subjects were previously diagnosed with IGT according to an abnormal response to a 120-min 75 g OGTT and in those subjects, as well as in NGT subjects, glucose tolerance status was confirmed at screening by an additional OGTT. A third group (n = 9) was diagnosed with Type II diabetes; five of them were treated with oral anti-diabetic drugs, that were stopped at least 4 weeks before the study. All subjects were on a weight maintaining diet for at least 1 month prior to testing. Subjects characteristics at recruitment are shown in Table 1 .
Over a period of 8±10 weeks, all subjects underwent in random order and in duplicate: 1) a continuous infusion of glucose with model assessment (CIGMA); 2) an insulin-modified FSIVGTT; 3) a short ITT combined with a homeostasis model assessment (HOMA), the ITT immediately following HOMA sampling. Tests were carried out at least 7 days apart. All volunteers were advised not to engage in unusual physical exercise for 3 days before each test. Subjects fasted from 2200 hours the previous evening. In order to minimise exercise before tests, they were advised not to exert themselves when coming to the visit (taxis were provided for the journey). Height, weight, and waist-to-hip ratio were measured on the first test day.
Methods. During each test, two antecubital cannulae, one in each arm, were inserted under local anaesthesia. The sampled arm was wrapped in electrical blankets to provide ªarterializ-edº blood. The CIGMA test consisted of a 180 mg × min ±1 × m ±2 glucose infusion for 120 min (infusion rate equivalent to 5 mg/ kg (ideal body weight)/min). The continuous low-dose infusion of glucose was started at time 0 min, with sampling at 110, 115, 120 min for glucose, RIA and specific insulin (2-h estimates). The reciprocal mean fasting RIA (or specific) insulin [±10, ±5, and 0 min; reciprocal of fasting plasma insulin concentration (FPI
±1
)] was also used as surrogate estimate for insulin sensitivity.
The modified FSIVGTT test used an intravenous glucose bolus (0.3 g/kg; 50 % solution) followed by a 5-min insulin infusion starting 20 min later (0.02 IU/kg in 4.5 % albumin (Zenalb 4.5 %, BioProduct Laboratory, Elstree, UK)) with 3 h blood sampling. Following basal sampling (±15, ±10, ±5 and 0 min), intravenous glucose was given at 0 min, then sampling followed at 3, 4, 5, 6, 8, 10, 12, 14, 16 and 19 min; at 20 min, insulin infusion was given, while sampling continued at 22, 24, 26, 28, 30, 33, 36, 40, 50, 60, 70, 80 , 100, 120, 140, 160, 180. Radioimmunoassay insulin and glucose were assayed on all samples.
For the short ITT, body weight was used to calculate the amount of intravenous insulin (0.05 IU/kg in 4.5 % albumin solution). Three fasting samples were taken at 5 min intervals immediately after insertion of the cannulae for immunoreactive (RIA) and specific insulin and glucose assays for HOMA modelling (HOMA-CIGMA version 2.1 [36] ). Thereafter, bolus insulin (0.05 IU/kg) was given at time 0 min, and sampling continued at times 1, 3, 5, 7, 9, 11, 13, 15 min for glucose assay. After completion of each test, subjects were provided with a light meal and advised of the possibility of reactive hypoglycaemia. After completion of the ITT, intravenous glucose (10 % glucose solution, 300 ml/h for 30 min) was also given.
Assays. Plasma glucose was measured with a hexokinase UVenzymatic method kit (Gluco-Quant Glucose, Boehringer Mannheim-BCL, Lewed, UK; assay range 0±22.2 mmol/l). Plasma immunoreactive insulin was assayed with either a double antibody RIA with 125 I labelled insulin (immunoreactive insulin), with an antiserum generated in guinea pig against human insulin and a sepharose anti-guinea pig IgG generated in sheep (Pharmacia Insulin RIA 100 Kit, Pharmacia, Milton Keynes, UK; assay range 3±240 mU/l or 22.2±1781.0 pmol/l). Specific insulin was measured with two-site sandwich ELISA. Biotinylated second antibody was detected by Streptavidin-Biotin horseradish peroxidase. Standards: Human Monocomponent Insulin with antibodies; 1) HUI-018-Murine monoclonal coating antibody and 2) OXI±Murine monoclonal, biotinylated with NHS-Biotin (Novo Nordisk Morham, Heathfield, UK and Novo Nordisk Immunochemical Department, Bagsvaerd, Denmark). Haemoglobin A 1 c was measured by HPLC based on charge separation using spherical cation exchange gel with Bio-rad reagent set and DIAMAT Automated Glycosylated Haemoglobin Analyser (Bio-rad Laboratories, Hemel Hempstead, UK). Samples for RIA insulin, specific insulin and C peptide were assayed in duplicate and for glucose in singleton.
Definition and calculation of measures of insulin sensitivity. The effect of an increment in plasma insulin to enhance the fractional net disappearance of glucose from the extracellular compartment of glucose distribution is represented by S I . The insulin sensitivity index calculated from the insulin-modified FSIVGTT using the Minimal Model approach (MinMod 2.0) [13, 17] . Homeostasis model assessment %S was assessed from fasting plasma glucose and insulin (mean of three baseline samples taken at 5 min intervals) and 2-h CIGMA %S from achieved plasma glucose and insulin (mean of 3 samples at 110, 115, and 120 min). Insulin tolerance test K g , the first order rate constant for glucose disappearance rate, estimated from the slope of the regression line of ln plasma glucose compared with time (from 3 to 15 min after the insulin bolus). Reciprocal of Fasting Plasma Insulin was obtained from HOMA day values.
Comparison between tests. The methodology used for comparing different tests measuring the same underlying physiological variable was described previously [34] and covers three aspects : (1) the ability of a test to discriminate between different subjects and comparison of discrimination between different tests; (2) the underlying correlation between pairs of tests adjusting for the attenuating effect of within subject variation; and (3) in cases where the relation between a pair of tests is approximately linear, unbiased estimation of the line of equivalence between them [34] .
Discrimination between subjects. For comparing s tests, each measuring the same physiological variable, done k times on each of n subjects, with a random test order, for each subject, the model is: X ijh = m h + a ih + e ijh ; for i = 1 . .. n, j = 1 . .. k and h = 1 . .. s (1) where X ijh is the result of the h'th test done for the j'th time on the i'th subject, m h is the mean value of the variable in question on the scale of test h and a ih is the`true' value of the i'th subject, measured on the scale of test h as a deviation from the mean of that test (thus, for each test h, S i=1,n a ih = 0). The e ijh represents day to day (biological and assay) variation, assumed to be a normally distributed random variable with mean zero, and variance s h 2 . Test results can be transformed if necessary to ensure homoscedasticity of the error term. Considering ini- (1) is a one-way analysis of variance (ANOVA). In our experiments, subjects were selected to span a range of glucose tolerance and not randomly chosen and subject effects a i are considered fixed rather than random.
Discriminant ratio. As a measure of the ability of a test to discriminate between subjects, the discriminant ratio (DR) is the ratio of the underlying between-subject to the within-subject SD. Using the standard unbiased estimates of the between and within-subject variances this can be estimated by:
where MS B and MS W are the between and within-subject mean squares from a standard one-way ANOVA. Equations calculating confidence limits for DRs and a test for the equivalence of several DRs have been derived [34] .
Correlation between pairs of tests. The nature of the relation between tests can be examined by plotting the subject means for the first test against those for the second. In many cases, the relation will be approximately linear and the degree of correlation assessed using Pearson product-moment correlation coefficient r. In the presence of within-subject variation, the sample correlation coefficient underestimates, however, the true correlation between tests (attenuation) and the coefficient can be adjusted to give an estimate of the underlying correlation:
where h is the attenuation factor
DRM h = DR h´Ö k is the DR for the subject mean values over all days and DR h is the DR of test h, h = 1, 2. When the relation between tests is clearly non-linear, the Spearman rank correlation coefficient r s should be used in place of r, although no universal formula exists for the attenuation of r s .
Unbiased estimation of linear relation. When the relation between a pair of tests is linear, it may be useful to obtain unbiased estimates of the gradient and intercept, although linear regression gives biased estimates because it only considers errors in the dependent variable. The ªperpendicular least squares, properly weightedº method estimates the variables of the underlying linear relation allowing for measurement error in both variables [29] . where S xx = S i=1,n (x i ±m x ) 2 , S yy = S i=1,n (y i ±m y ) 2 , S xy = S i=1,n (x i ±m x ).(y i ±m y ), m x and m y are the means of the x i and y i respectively, q = s y 2 /s x 2 and s x and s y are the within-subject SD of the x i and y i respectively. The intercept is estimated as a = m y ±b.m x Other statistical analyses. Differences between groups of subjects were assessed with either unpaired Student's t test or using a one-way analysis of variance (ANOVA) and StudentNewman-Keuls multiple comparison tests, or Kruskal-Wallis non-parametric ANOVA and Dunn's multiple comparison tests. Significance was considered for p < 0.05.
Results
The characteristics of test subjects at inclusion are given in Table 1 . Body mass index was greater in IGT than in the NGT subjects, with no statistically significant difference between Type II diabetic subjects and IGT. Waist-to-hip ratio and body surface area were larger (p < 0.05) in subjects with Type II diabetes and IGT than in NGT subjects. Type II diabetic subjects had reduced K g and increased glucose both fasting and 2 h after CIGMA. Subjects with IGT had intermediate values, that were only different (p < 0.01) from NGT after CIGMA. Type II diabetic subjects had higher (p < 0.05) fasting insulin but following the glucose infusion this was no longer significantly different from that of normal subjects. There were no differences between groups in the glucose response to ITT (not shown).
Insulin sensitivity estimates for each group of subjects were obtained by MinMod analysis of the FSIVGTT (S I FSIVGTT), HOMA and CIGMA modelling (HOMA %S and 2-h CIGMA %S), and by the short ITT (K g ITT). Insulin sensitivity was also inferred from reciprocal fasting plasma insulin (FPI ±1 ). MinMod analysis of the insulin-modified FSIVGTT was convergent for both replicate tests in 13 subjects but failed to converge on one occasion in 7 subjects (2 IGT and 5 Type II diabetic) and on both occasions in 4 (1 IGT and 3 Type II diabetic). Thus, MinMod analysis of the insulin-modified FSIVGTT in 24 subjects provided repeat measurements of S I in all NGT, in 5/8 of IGT and in only 1/9 of Type II diabetic subjects. The ªMinMod unsuccessfulº group had higher (p < 0.05) BMI, waist-tohip ratio, fasting plasma glucose and insulin and lower K g[10±20 min] IVGTT , HOMA %S, 2-h CIGMA %S and K gITT . Although the insulin infusion used to modify the FSIVGTT was in the low range (0.02 UI/kg), it was sufficient to induce mild symptomatic hypoglycaemia in 2 NGT subjects.
Normal glucose tolerant subjects were more insulin sensitive than IGT or Type II diabetic subjects when assessed by FPI ±1 or HOMA %S than Type II diabetic subjects when assessed by K g ITT (not shown).
Difference compared with mean plots for duplicate tests (test a vs test b ) were heteroscedastic for HOMA, CIGMA, ITT and FPI
±1
, and homoscedastic after log transformation. FSIVGTT values were homoscedastic. Difference compared with mean plots on repeat test days are shown in Fig. 1 . The differences observed between test replicates were largest relative to subject range for K g ITT and also larger with specific than RIA insulin for HOMA and 2-h CIG-MA %S. The largest day-to-day variations were found in subjects in whom S I could not be determined on repeat days; data plots for subjects in whom S I was obtainable twice (n = 13) are shown in Fig. 1 .
The underlying between-subject SD and global within-subject SD for each estimate of insulin sensitivity are shown on Table 2 , together with the DR and confidence intervals, for all subjects (n = 24) and for the subgroup of ªFSIVGTT successfulº subjects (n = 13). In the combined group of 24 subjects, the DR of K g ITT was smaller than all other tests, except 2-h CIGMA %S (specific insulin). Other tests DRs were relatively close, with 2-h CIGMA %S (RIA insulin) having a greater DR than HOMA %S. In the ªFSIVGTT successfulº group (n = 13), absolute DRs values were smaller, owing to the reduced range of individual sensitivity values resulting from exclusion of subjects with low S I . The DR of S I FSIVGTT was similar to that of K g ITT whereas 2-h CIGMA %S (RIA insulin) had an appreciably greater DR value.
Rank correlation between tests was generally high, once values were adjusted for attenuation. The measured Pearson correlation coefficients and their values adjusted for attenuation are shown on Table 3 . Correlation between results of insulin sensitivity obtained in the MinMod successful group are shown as scattergrams in Fig. 2 . In these subjects, S I correlated well with FPI ±1 , HOMA %S (RIA insulin) and 2-h CIGMA %S (RIA or specific insulin), since the corrected coefficient were greater than 90 % of theoretical maximum expected values when imprecision was taken into account. Correlation of K g ITT with other tests was not so good (Table 3) . The a and b coefficients of equations expressing the lines of ªtrueº equivalence relating two given tests are described in Table 4 . These coefficients are provided for all combinations of estimates of insulin sensitivity and enable construction of ªtrueº lines of equivalence (y = a + bx, i. e. the lines between physiologically equivalent points of insulin sensitivity measured by two different methods) for any pair of tests, taking into account random variation in both variables measured. These slopes and intercepts are unbiased and independent of V w .
Discussion
This study was undertaken to compare the discriminating performance in a series of in vivo insulin sensitivity tests. Our data show that cheap, simple and non-invasive insulin sensitivity indices such as FPI ±1 and HOMA or 2-h CIGMA modelling of %S were as able to discriminate differences between subjects as the more widely used FSIVGTT-MinMod or better than the more invasive ITT. We simultaneously compared different tests for intra-subject variability, discrimination, correlation and ªlines of equivalenceº. The ability of a test to distinguish individual subjects has been assessed by its discriminant ratio (DR) and the relation between tests has been expressed as Pearson correlation coefficients adjusted for the attenuating effect of within-subject variation. In addition, we present a and b coefficients for the equations of the lines of equivalence between pairs of tests.
Reciprocal fasting plasma insulin, HOMA %S or 2-h CIGMA %S achieved as high a DR as did the more intensive insulin sensitivity tests, FSIVGTT and ITT. Apart from the ITT, these tests showed high intercorrelation coefficients, and good correla- Table 2 . Tests precision and discrimination expressed as underlying between-subject standard deviation (SD U ) and as global within-subject standard deviation (SD W ), and test discriminant ratio (DR) All correlations were calculated from means of tests duplicates (from log results) in n = 24 subjects (7 NGT, 8 IGT and 9 with Type II diabetes) except for correlations between FSIVGTTMinMod (n = 13 subjects). For correlation between FPI 1 or HOMA %S (RIA insulin) and other estimates, fasting glucose and insulin concentrations were obtained from the mean of tests done on different days tion with S I . The 2-h CIGMA %S (RIA insulin) had the best performance but additional studies would be needed to confirm whether this is so. This test is easier to do than the FSIVGTT and also provides measures of beta-cell function and glucose tolerance [23, 25] . The less precise results with CIGMA using specific rather than RIA insulin show how the results are critical on assay methods. The short insulin tolerance test performance was less than all other tests, due to poor reproducibility. The performance of FSIVGTT-MinMod S I was similar to that of FPI ±1 , HOMA and 2-h CIGMA %S.
With the amount of insulin used in our study, it was expected from all the previously published data that FSIVGTT-MinMod would be more successful for ascertaining insulin sensitivity in the less hyperglycaemic and insulin resistant subjects. It is possible that extending the sampling period for longer, or addition of an artificial point at 240 or 360 min could have decreased the failure rate in IGT and Type II diabetic subjects. The FSIVGTT is often considered a more feasible alternative to the euglycaemic clamp against which it has been validated [18] . It is, however, less efficient than some other tests that provide data across a greater range of patients [20, 21] . We used a bolus insulin dose of 0.02 IU/kg in the insulin-modified FSIVGTT as recommended [38] and similar to that used in another study in which it was shown that this dose is a good match to peripheral plasma glucose and insulin responses from a tolbutamide-modified FSIVGTT [39] . Although it is possible that a larger insulin bolus could make the test more applicable in insulin resistant and diabetic patients, the dose we used was sufficient to induce hypoglycaemia in some normal subjects.
We found a rate of convergence failure with bolus insulin of 0.02 IU/kg of about 38 % (IGT) and about 90 % (Type II diabetes), and the ªfailureº group were predominantly those with low insulin sensitivity values on other tests, this was not unexpected since they had IGT or diabetes. A 50 % failure of a 22-samples or 12-samples FSIVGTT (modified with 0.03 IU/ kg insulin) to provide insulin sensitivity in non-diabetic, mostly obese, subjects has been reported [20] . A larger dose (0.03±0.05 IU/kg) may have provided more estimates of insulin sensitivity, but would probably produce hypoglycaemia in more subjects. Although it might seem reasonable to vary the dose according to the person being studied, this is likely to produce systematic differences in the resulting measure of insulin sensitivity. Our data suggest that exogenous insulin should be used at a low (0.02 IU/kg) dose when a FSIVGTT is contemplated in NGT and IGT subjects with previously unknown insulin sensitivity.
The repeatability of tolbutamide-modified FSIVGTT-MinMod has been reported [40] as similar to that of a clamp in NGT subjects (CV 14 %), although in another report [41] the CV was 22 % and we found a CV of about 30 %. Procedures with fewer samples may be applicable in NGT subjects [42, 43] , although it has been found [44] that reduced sampling gives less precision, with CVs (for n samples) of 18 (30), 29 (12) , and 27 % (13). It is doubtful whether reduced sampling would be effective in subjects with IGT or diabetes who can fail to converge with results from 31 samples.
Studies on reproducibility for CIGMA estimates show that the inter-assay CV of plasma insulin measurement is a major component of imprecision [23, 27] . This was shown in the present study, in which use of a less precise, but presumably more accurate, specific insulin assay gave less good discrimination. Homeostasis Model Assessment evaluates fasting glucose and insulin measurements and requires precise and sensitive assays. We took three fasting samples over 10 min to improve precision and to take into account the 15 min pulsatility of insulin secretion in normal subjects [45] . Although we found HOMA gave similar DRs to 2-h CIGMA, if less precise glucose and insulin measurements were available CIG-MA might be relatively more applicable than the present study indicates.
Our data suggest that in NGT and IGT categories, no single test is definitely superior to another, although the 2-h CIGMA %S (RIA insulin) is perhaps more informative. This test is easier to carry out than the FSIVGTT and also gives a measure of betacell function and of glucose tolerance. The relative superiority of FPI ±1 , HOMA %S and CIGMA %S compared with FSIVGTT-MinMod is somewhat arguable in subjects in which fits were obtained with the Minimal Model.
A simple method for quantification of insulin sensitivity from an IVGTT (K g /D incremental IRI 0±40 min ) has been reported [46] . This alternative analysis could be of value in conditions where traditional reference procedures (clamp or FSIVGTT-MinMod) are not feasible. We could not compare its performance in this study, as exogenous insulin during the FSIVGTT rendered impossible the determination of incremental endogenous insulin beyond the 20th min.
The short ITT is reported to have good precision (at an insulin dose of 0.1 UI/kg), with a CV of 6 % in obese NGT subjects [47] and 9 % in normal subjects [28] , whereas in non-obese NGT subjects and using a 0.05 UI/kg insulin bolus within-subject CVs of 13 % has been reported [48] . With this dose we found CVs of about 30 % in our group spanning the range of glucose tolerance. It is possible that the insulin dose might have contributed to the discrepancy, although it was sufficient to induce hypoglycaemia in some subjects.
Reciprocal of fasting plasma insulin concentration alone performed well as a surrogate estimate of insulin sensitivity, both in terms of DR and of correlation with other tests. This is in accordance with a previous report [49] in which a correlation between FPI and resistance to insulin-mediated glucose uptake in normal and diabetic subjects during an insulin suppression test was described and also a negative correlation with insulin sensitivity when the latter was less than 3 min ±1 /mU ml ±1 (MinMod analysis) in lean and obese non-diabetic subjects [18] . A correlation (p < 0.001) between fasting plasma insulin and insulin sensitivity was also described in IGT subjects [50] . A non-linear relation with FPI using FSIVGTT-MinMod in non-diabetic subjects with varying degrees of obesity has been described [51] and a negative correlation was also reported during euglycaemic clamps. Since FPI is increased when impaired insulin sensitivity is present, secondary to the ªresistance-inducedº increment in plasma glucose, these associations would be expected. The HOMA model shows that re-duction of FPI from the error signal in the homeostatic feed-back loops introduced by deficient insulin secretion is small, which explains why FPI ±1 alone is a reasonable estimator of insulin sensitivity. Nevertheless, the addition of measurement of fasting plasma glucose allows for the error signal and, in theory, HOMA provides a more accurate measure of insulin sensitivity, alongside a beta-cell function estimate.
It has been suggested [9] that the ideal method for measuring insulin sensitivity should satisfy five requirements: 1) to achieve insulin concentrations high enough to stimulate glucose metabolism and detect small differences in sensitivity of glucose uptake to insulin; 2) to distinguish between peripheral and hepatic insulin sensitivity; 3) to measure steady-state conditions; 4) to rest on physiologically sound assumptions about body glucose system and 5) to achieve a degree of hyperglycaemia not overtly nonphysiological. Although no such perfect test has yet been proposed for routine use, HOMA fulfils three criteria and 2-h CIGMA four criteria. A candidate test should score high in analysis of test performance and be simple, safe and cheap. Two large studies illustrate the application of HOMA for assessing for the natural course of diabetes [52] or the response to pharmacological intervention [11] .
In conclusion, simple non-invasive estimates can be used to discriminate subjects for their insulin sensitivity. Continuous infusion of glucose with model assessment appears to be a better discriminatory test in precision and agreement analysis. The HOMA-CIGMA models, using RIA insulin, are candidates for routine measurement of insulin sensitivity. Using specific insulin as input offered no direct advantage over RIA insulin, although this may change when more precise specific assays are used. Different studies have used different methods of assessing insulin sensitivity and the methodology used here allows for unbiased lines of equivalence to be established between tests, a practical means of comparing results between studies, although allowance needs to be made when different procedures or assays have been used.
